Anaptys Announces Stock Repurchase Plan

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

Anaptys Announces Participation in September Investor Conferences

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update